EICHORPublic-registry site landscape for NCT07703956, “Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults”, a Schizophrenia study sponsored by Vigonvita Life Sciences. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07703956 (registry record) |
| Study title | Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults |
| Official title | A Phase 2,Multicenter, Randomized, Double-blind, Placebo and Active Comparator Parallel-controlled Study to Evaluate the Safety and Efficacy of VV119 in Adults With Acute Schizophrenia |
| Sponsor | Vigonvita Life Sciences |
| Condition(s) | Schizophrenia |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | China |
At Beijing Anding Hospital of Capital Medical University — one of the facilities listed on this trial — 1 other study is actively recruiting Schizophrenia patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07703956.
Eichor generates a preliminary site-risk snapshot for NCT07703956 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Schizophrenia trials
More from Vigonvita Life Sciences
← Eichor home · All tracked trials · Schizophrenia studies · Weekly briefs
